$VSEE
VSEE HEALTH, INC.

2023 Q1 Form 10-Q Financial Statement

#000110465923060899 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $707.6K $543.2K
YoY Change 30.27%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $707.6K $543.2K
YoY Change 30.27%
Operating Profit -$707.6K -$543.2K
YoY Change 30.27%
Interest Expense -$1.187M $15.82K
YoY Change -7603.48%
% of Operating Profit
Other Income/Expense, Net -$1.187M $15.82K
YoY Change -7603.95%
Pretax Income -$1.895M -$527.4K
YoY Change 259.27%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.895M -$527.4K
YoY Change 259.27%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$0.04
Diluted Earnings Per Share -$0.45 -$0.04
COMMON SHARES
Basic Shares Outstanding 4.169M 14.93M
Diluted Shares Outstanding 4.169M 14.93M

Balance Sheet

Concept 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.33K $509.7K
YoY Change -96.8%
Cash & Equivalents $16.33K $509.7K
Short-Term Investments
Other Short-Term Assets $52.50K $367.0K
YoY Change -85.7%
Inventory
Prepaid Expenses $52.50K $367.0K
Receivables
Other Receivables
Total Short-Term Assets $68.83K $876.7K
YoY Change -92.15%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $7.603M $116.7M
YoY Change -93.49%
Other Assets
YoY Change
Total Long-Term Assets $7.603M $116.7M
YoY Change -93.49%
TOTAL ASSETS
Total Short-Term Assets $68.83K $876.7K
Total Long-Term Assets $7.603M $116.7M
Total Assets $7.671M $117.6M
YoY Change -93.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.092M $342.5K
YoY Change 510.74%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.070M $43.90K
YoY Change 2336.99%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.013M $386.4K
YoY Change 1197.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.370M $4.370M
YoY Change 0.0%
Total Long-Term Liabilities $4.370M $4.370M
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.013M $386.4K
Total Long-Term Liabilities $4.370M $4.370M
Total Liabilities $9.383M $4.756M
YoY Change 97.28%
SHAREHOLDERS EQUITY
Retained Earnings -$9.615M -$3.862M
YoY Change 148.94%
Common Stock $344.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.107M -$3.862M
YoY Change
Total Liabilities & Shareholders Equity $7.671M $117.6M
YoY Change -93.48%

Cashflow Statement

Concept 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.895M -$527.4K
YoY Change 259.27%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$340.7K -$250.3K
YoY Change 36.11%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 250.0K
YoY Change
NET CHANGE
Cash From Operating Activities -340.7K -250.3K
Cash From Investing Activities
Cash From Financing Activities 250.0K
Net Change In Cash -90.67K -250.3K
YoY Change -63.78%
FREE CASH FLOW
Cash From Operating Activities -$340.7K -$250.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dhacu Redemption Of Shares Calculated Based On Number Of Business Days Prior To Consummation Of Business Combination
RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination
P2D
CY2023Q1 dhacu Redemption Period Upon Closure
RedemptionPeriodUponClosure
P10D
CY2023Q1 dhacu Redemption Period Upon Closure
RedemptionPeriodUponClosure
P10D
CY2023Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001864531
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 dhacu Extension Period To Consummate Business Combination
ExtensionPeriodToConsummateBusinessCombination
P3M
CY2022Q4 dhacu Maximum Extension Period To Consummate Business Combination
MaximumExtensionPeriodToConsummateBusinessCombination
P9M
CY2023Q1 dhacu Fair Value Liabilities Level2 To Level1 Transfer Amount
FairValueLiabilitiesLevel2ToLevel1TransferAmount
0
CY2022Q4 dhacu Fair Value Liabilities Level2 To Level1 Transfer Amount
FairValueLiabilitiesLevel2ToLevel1TransferAmount
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q1 dhacu Extension Fee If Form S4 Registration Statement Is Filed
ExtensionFeeIfFormS4RegistrationStatementIsFiled
P3M
CY2023Q1 dhacu Period To Regain Compliance
PeriodToRegainCompliance
P10D
CY2023Q1 dhacu Threshold Consecutive Trading Days Prior To Date Of Letter
ThresholdConsecutiveTradingDaysPriorToDateOfLetter
P30D
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-250290
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41015
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
DIGITAL HEALTH ACQUISITION CORP.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-2970927
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
980 N Federal Hwy #304
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33432
CY2023Q1 dei City Area Code
CityAreaCode
561
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
672-7068
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4183123
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16331
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106998
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
52500
CY2023Q1 us-gaap Assets Current
AssetsCurrent
68831
CY2022Q4 us-gaap Assets Current
AssetsCurrent
106998
CY2023Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
7602649
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
7527369
CY2023Q1 us-gaap Assets
Assets
7671480
CY2022Q4 us-gaap Assets
Assets
7634367
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2091536
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1886312
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
187225
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
187225
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
425939
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
292800
CY2023Q1 dhacu Promissory Note Related Party Classified Current
PromissoryNoteRelatedPartyClassifiedCurrent
600000
CY2022Q4 dhacu Promissory Note Related Party Classified Current
PromissoryNoteRelatedPartyClassifiedCurrent
350000
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
43900
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
43900
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
329953
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
364711
CY2023Q1 dhacu Pipe Forward Contract Derivative
PipeForwardContractDerivative
1334616
CY2022Q4 dhacu Pipe Forward Contract Derivative
PipeForwardContractDerivative
170666
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5013169
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3295614
CY2023Q1 dhacu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
4370000
CY2022Q4 dhacu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
4370000
CY2023Q1 us-gaap Liabilities
Liabilities
9383169
CY2022Q4 us-gaap Liabilities
Liabilities
7665614
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
507171
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
292973
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-250290
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9614558
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7719916
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-9107038
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7426596
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7671480
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7634367
CY2023Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
707592
CY2022Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
543179
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-707592
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-543179
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
133138
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-34758
CY2023Q1 dhacu Change In Fair Value Of Pipe Forward Contract Derivative
ChangeInFairValueOfPipeForwardContractDerivative
1163950
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
75280
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
15819
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1187050
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15819
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1894642
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-527360
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1894642
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-527360
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4168567
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4168567
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14932000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14932000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-7426596
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
214200
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1894642
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-9107038
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3334468
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-527360
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3861828
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1894642
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-527360
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
75280
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
15819
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-34758
CY2023Q1 dhacu Change In Fair Value Of Pipe Forward Contract Derivative
ChangeInFairValueOfPipeForwardContractDerivative
1163950
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
52500
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-90591
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
419424
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
202298
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
133139
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-340667
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
250000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
250000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-90667
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106998
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
760012
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16331
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
509722
CY2023Q1 us-gaap Stock Issued1
StockIssued1
214200
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Digital Health Acquisition Corp. (the “Company” or “DHAC”) is a blank check company incorporated as a Delaware corporation on March 30, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses (the “Business Combination”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On June 9, 2022, DHAC Merger Sub I, Inc. (“Merger Sub I”), a Delaware corporation and a wholly owned subsidiary of the Company, was formed. On June 9, 2022, DHAC Merger Sub II, Inc. (“Merger Sub II”), a Texas corporation and a wholly owned subsidiary of the Company, was formed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2023, the Company had not commenced any significant operations. All activity for the period from inception, the date which operations commenced, through March 31, 2023 relates to the Company’s formation, the Company’s Initial Public Offering (as defined below), and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering (as defined below). The Company has selected December 31 as its fiscal year end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company’s Initial Public Offering was declared effective on November 3, 2021. On November 8, 2021, the Company consummated the Initial Public Offering of 11,500,000 units (the “Units” and, with respect to the shares of common stock included in the Units sold, the “Public Shares”), which includes the full exercise by the underwriter of its over-allotment option in the amount of 1,500,000 Units, at $10.00 per Unit, generating gross proceeds of $115,000,000, which is described in Note 3. On October 20, 2022, in connection with the stockholders meeting to approve the extension, 10,805,877 shares of DHAC’s common stock were redeemed leaving 694,123 shares subject to redemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 557,000 units (each, a “Private Placement Unit” and, collectively, the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to Digital Health Sponsor LLC (the “Sponsor”), generating gross proceeds of $5,570,000, which is described in Note 4. As of November 8, 2021, the Company received $3,680,000 from the proceeds of the Private Placement and recorded $1,890,000 in subscription receivable. The Sponsor paid the subscription in full on November 12, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Transaction costs amounted to $6,877,164, consisting of $1,955,000 of underwriting fees, $4,370,000 of deferred underwriting fees and $552,164 of other offering costs. In addition, cash of $9,478 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the Initial Public Offering on November 8, 2021, an amount of $116,725,000 ($10.15 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account (the “Trust Account”), invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act of 1940, as amended (the “Investment Company Act”). The Trust Account is intended as a holding place for funds pending the earliest to occur of either (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the Company’s public shares if the Company does not complete the initial Business Combination within 21 months from the closing of the Initial Public Offering (as currently extended and as may be further extended in accordance with the Amended and Restated Certificate of Incorporation) or (B) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity; or (iii) absent an initial Business Combination within 21 months from the closing of the Initial Public Offering (as currently extended and as may be further extended in accordance with the Amended and Restated Certificate of Incorporation), the Company’s return of the funds held in the Trust Account to the Company’s public stockholders as part of the Company’s redemption of the public shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On October 20, 2022, stockholders of DHAC approved a proposal to amend DHAC’s amended and restated certificate of incorporation to (a) extend the date by which DHAC has to consummate a business combination (the “Extension”) for an additional <span style="-sec-ix-hidden:Hidden_o3QCAfrYWEKt-yYyFhBgwA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> (3) months, from November 8, 2022 to February 8, 2023, (b) provide DHAC’s board of directors the ability to further extend the date by which </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">DHAC has to consummate a business combination up to three (3) additional times for three (3) months each time, for a maximum of <span style="-sec-ix-hidden:Hidden_qX69ZafsikepRDxgmsxAUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nine</span></span> (9) additional months if the Sponsor pays an amount equal to $350,000 for each three-month extension (the “Extension Fee”), which amount shall be deposited in the trust account of DHAC; provided, that if as of the time of an extension DHAC has filed a Form S-4 registration statement in connection with its initial business combination, then no Extension Fee would be required in connection with such extension; provided further that for each <span style="-sec-ix-hidden:Hidden_fAXcKhyJrk6ZRJvGEwmZRA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>-month extension (if any) following such extension where no deposit into the Trust Account or other payment has been made, an Extension Fee is required, and (c) allow for DHAC to provide redemption rights to DHAC’s public stockholders in accordance with the requirements of the amended and restated certificate of incorporation without complying with the tender offer rules. In connection with such stockholder vote, an aggregate of 10,805,877 shares of DHAC’s common stock were redeemed leaving 4,156,123 shares issued and outstanding and entitled to vote as of October 20, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the net balance in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held and taxes payable on the income earned on the Trust Account) at the time of the signing an agreement to enter into a Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company will provide the Company’s public stockholders with the opportunity to redeem all or a portion of their common shares in connection with the initial Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) without a stockholder vote by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek stockholder approval under applicable law or stock exchange listing requirement. The public stockholders will be entitled to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of <span style="-sec-ix-hidden:Hidden_Ot8kV3N-X0CRScvwhpycyw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, divided by the number of then outstanding public shares, subject to the limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The amount in the Trust Account was initially anticipated to be $10.15 per public share. On October 26, 2022, in connection with the approval of the extension, the Sponsor deposited $350,000 into the Trust Account for the first three-month extension, as such the amount in the Trust Account is anticipated to be $10.65 per public share. On February 2, 2023 the Company announced a second extension of the date by which the Company has to consummate a business combination from February 8, 2023 to May 8, 2023. On May 8, 2023 the Company announced a third extension of the date by which the Company has to consummate a business combination from May 8, 2023 to August 8, 2023 (as extended, the “Combination Period”) and deposited $350,000 into the Trust Account for such extension. The May extension is the second of three additional three-month extensions permitted under the Company’s governing documents and provides the Company with additional time to complete its initial business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Company received a letter (the “Letter”) from the staff at The Nasdaq Global Market (“Nasdaq Global”) notifying the Company that for the <span style="-sec-ix-hidden:Hidden_lId7EBoM102qWEwuhFqlwA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30</span></span> consecutive trading days prior to the date of the Letter, the Company’s securities listed on Nasdaq Global (including the Common Stock, Units and Warrants) (the “Securities”) had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“MVLS”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s Securities on Nasdaq Global. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s Securities on Nasdaq Global.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with Nasdaq listing rule 5810(c)(3)(C), the Company has 180 calendar days, or until September 27, 2023, to regain compliance. The Letter notes that to regain compliance, the Company’s Securities must trade at or above a level such that the Company’s MVLS closes at or above $50,000,000 for a minimum of <span style="-sec-ix-hidden:Hidden_mzflXRA_6kK8T1xV4_6yJQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> consecutive business days during the compliance period, which ends September 27, 2023. The Letter further notes that if the Company is unable to satisfy the MVLS requirement prior to such date, the Company may be eligible to transfer the listing of its Securities to The Nasdaq Capital Market (provided that it then satisfies the requirements for continued listing on that market). If the Company does not regain compliance by September 27, 2023, Nasdaq staff will provide written notice to the Company that its Securities are subject to delisting. At that time, the Company may appeal any such delisting determination to a hearings panel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">However, if the Company is unable to complete its initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than <span style="-sec-ix-hidden:Hidden_0v06Q1ALSkmWNN8O7aoClQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any) and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, liquidate and dissolve, subject, in each case, to the Company’s obligations under Delaware law to provide for claims of creditors and in all cases subject to the other requirements of applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The shares of common stock subject to redemption are recorded at a redemption value and classified as temporary equity in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.” In such case, and in accordance with the closing conditions set forth in the Company’s business Combination Agreement (as defined below), the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Sponsor, along with certain advisors, officers and directors, has entered into a letter agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their founder shares (as defined in Note 5) and public shares in connection with the completion of the initial Business Combination; (ii) waive their redemption rights with respect to their founder shares and public shares in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the Company’s public shares if the Company have not consummated an initial Business Combination within the Combination Period or (B) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity; (iii) waive their rights to liquidating distributions from the Trust Account with respect to their founder shares if the Company fails to complete the initial Business Combination within the Combination Period, although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the initial Business Combination within the prescribed time frame; and (iv) vote any founder shares held by them and any public shares purchased during or after the Initial Public Offering (including in open market and privately negotiated transactions) in favor of the initial Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company have entered into a written letter of intent, confidentiality or other similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.15 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.15 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor have the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that the Sponsor would be able to satisfy those obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">On June 15, 2022, DHAC, entered into a business combination agreement, by and among DHAC Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of DHAC (“Merger Sub I”), DHAC Merger Sub II, Inc., a Texas corporation and a wholly owned subsidiary of DHAC (“Merger Sub II” and together with Merger Sub I, the “Merger Subs”), VSee Lab, Inc., a Delaware corporation (“VSee”) and iDoc Virtual Telehealth Solutions, Inc., a Texas corporation (“iDoc”). The business combination agreement and the transactions contemplated thereby (collectively, the “Business Combination”) were unanimously approved by the boards of directors of each of DHAC, VSee and iDoc on June 15, 2022. On August 9, 2022, DHAC, Merger Sub I, Merger Sub II, VSee and iDoc entered into the First Amended and Restated Business Combination Agreement to provide for the concurrent execution of financing documents for a PIPE consisting of convertible notes and warrants and delivery of the Cassel Salpeter’s opinion to the Board. On </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">October 6, 2022, DHAC, Merger Sub I, Merger Sub II, VSee and iDoc entered into a Second Amended and Restated Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”) to make the consideration payable to VSee and iDoc stockholders 100% DHAC common stock and to provide for the concurrent execution of amended PIPE Financing documents providing for the issuance of the PIPE Shares and the PIPE Warrants further described on Note 6. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Business Combination Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the Business Combination Agreement and subject to the terms and conditions set forth therein, Merger Sub I will merge with and into VSee (the “VSee Merger”), with VSee surviving the VSee Merger as a wholly owned subsidiary of DHAC, and Merger Sub II will merge with and into iDoc (the “iDoc Merger” and, together with the VSee Merger, the “Mergers”), with iDoc surviving the iDoc Merger as a wholly owned subsidiary of DHAC. At the effective time of the Mergers (the “Effective Time”), DHAC will change its name to VSee Health, Inc.</p>
CY2023Q1 dhacu Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2023Q1 dhacu Transaction Costs
TransactionCosts
6877164
CY2023Q1 dhacu Sale Of Stock Underwriting Fees
SaleOfStockUnderwritingFees
1955000
CY2023Q1 dhacu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
4370000
CY2023Q1 dhacu Sale Of Stock Other Offering Costs
SaleOfStockOtherOfferingCosts
552164
CY2023Q1 dhacu Cash Held Outside Trust Account
CashHeldOutsideTrustAccount
9478
CY2022Q4 dhacu Number Of Extensions To Consummate Business Combination
NumberOfExtensionsToConsummateBusinessCombination
3
CY2022Q4 dhacu Extension Fee Payable By Sponsor
ExtensionFeePayableBySponsor
350000
CY2023Q1 dhacu Extension Fee For Each Additional Three Months Extension Period
ExtensionFeeForEachAdditionalThreeMonthsExtensionPeriod
0
CY2023Q1 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
10805877
CY2023Q1 dhacu Shares Issued And Outstanding Entitled To Vote
SharesIssuedAndOutstandingEntitledToVote
4156123
CY2023Q1 dhacu Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2023Q1 dhacu Threshold Minimum Aggregate Fair Market Value As Percentage Of Asset Held In Trust Account
ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetHeldInTrustAccount
80
CY2023Q1 dhacu Condition For Future Business Combination Threshold Percentage Ownership
ConditionForFutureBusinessCombinationThresholdPercentageOwnership
50
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.15
CY2023Q1 dhacu Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
100000
CY2023Q1 dhacu Condition For Future Business Combination Threshold Net Tangible Assets
ConditionForFutureBusinessCombinationThresholdNetTangibleAssets
5000001
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16331
CY2023Q1 dhacu Working Capital
WorkingCapital
4737038
CY2023Q1 dhacu Withdrawal Allowance On Interest From Trust
WithdrawalAllowanceOnInterestFromTrust
207300
CY2023Q1 dhacu Proceeds Held In Trust Account Used To Repay Working Capital Loans
ProceedsHeldInTrustAccountUsedToRepayWorkingCapitalLoans
0
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. The most significant accounting estimates were the assumptions used to fair value the PIPE Forward Contract and the Bridge Note Bifurcated Derivative. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company has a significant cash balances at a financial institution which throughout the year regularly exceed the federally insured limited of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p>
CY2023Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
43900
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
43900
CY2021Q4 dhacu Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
2
CY2023Q1 dhacu Deferred Underwriting Commission Percent
DeferredUnderwritingCommissionPercent
3.8
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q1 dhacu Derivative Financial Instruments
DerivativeFinancialInstruments
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Derivative Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as bifurcated derivatives in accordance with ASC 815. Derivative instruments are recorded at fair value on the grant date and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the PIPE financing agreement is a derivative instrument and the Bridge Note’s early redemption provision is an embedded feature that is required to be bifurcated as a derivative. FASB ASC 470-20, “Debt with Conversion and Other Options,” addresses the allocation of proceeds from the issuance of debt into its debt and bifurcated derivative components. The Company applies this guidance to allocate the Bridge Note proceeds between the Bridge Note and the Bifurcated Derivative, using the residual method by allocating the principal first to fair value of the bifurcated derivative and then to the debt.</span></p>
CY2021Q4 dhacu Advance From Related Party For Expenses Incurred On Behalf Of Company
AdvanceFromRelatedPartyForExpensesIncurredOnBehalfOfCompany
402936
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y4M13D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y3M7D
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 dhacu Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2023Q1 dhacu Condition For Future Business Combination Threshold Net Tangible Assets
ConditionForFutureBusinessCombinationThresholdNetTangibleAssets
5000001
CY2023Q1 dhacu Months To Complete Acquisition Period
MonthsToCompleteAcquisitionPeriod
P21M
CY2023Q1 dhacu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12057000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12057000
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.50
CY2023Q1 dhacu Warrant Exercise Period Condition One
WarrantExercisePeriodConditionOne
P30D
CY2023Q1 dhacu Warrant Exercise Period Condition Two
WarrantExercisePeriodConditionTwo
P12M
CY2023Q1 dhacu Number Of Warrants Exercisable For Cash
NumberOfWarrantsExercisableForCash
0
CY2023Q1 dhacu Warrants Trading Days On Which Fair Market Value Of Shares Is Reported
WarrantsTradingDaysOnWhichFairMarketValueOfSharesIsReported
5
CY2023Q1 dhacu Warrants Trading Days On Which Fair Market Value Of Shares Is Reported
WarrantsTradingDaysOnWhichFairMarketValueOfSharesIsReported
5
CY2023Q1 dhacu Share Price Trigger Used To Measure Dilution Of Warrants
SharePriceTriggerUsedToMeasureDilutionOfWarrants
9.20
CY2023Q1 dhacu Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant
PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant
60
CY2023Q1 dhacu Share Price Trigger Used To Measure Dilution Of Warrants
SharePriceTriggerUsedToMeasureDilutionOfWarrants
9.20
CY2023Q1 dhacu Warrant Exercise Price Adjustment Multiple
WarrantExercisePriceAdjustmentMultiple
115
CY2023Q1 dhacu Warrant Redemption Condition Minimum Share Price
WarrantRedemptionConditionMinimumSharePrice
18.00
CY2023Q1 dhacu Warrant Redemption Price Adjustment Multiple
WarrantRedemptionPriceAdjustmentMultiple
180
CY2023Q1 dhacu Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2023Q1 dhacu Warrant Exercise Restriction Threshold Percent Of Common Stock Owned
WarrantExerciseRestrictionThresholdPercentOfCommonStockOwned
9.8
CY2023Q1 dhacu Exercise Of Warrants Fractional Shares Issued
ExerciseOfWarrantsFractionalSharesIssued
0
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
110472254
CY2022 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
10805877
CY2023Q1 dhacu Pipe Forward Contract Derivative
PipeForwardContractDerivative
1334616
CY2023Q1 dhacu Fair Value Of Bifurcated Derivative
FairValueOfBifurcatedDerivative
329953
CY2022Q4 dhacu Pipe Forward Contract Derivative
PipeForwardContractDerivative
170666
CY2022 dhacu Fair Value Of Bifurcated Derivative
FairValueOfBifurcatedDerivative
364711
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0476
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0494
CY2022 dhacu Share Based Compensation Arrangements By Probability Of Completing Business Combination
ShareBasedCompensationArrangementsByProbabilityOfCompletingBusinessCombination
0.95
CY2023Q1 dhacu Share Based Compensation Arrangements By Probability Of Completing Business Combination
ShareBasedCompensationArrangementsByProbabilityOfCompletingBusinessCombination
0.80
CY2023Q1 dhacu Fair Value Liabilities Level1 To Level2 Transfer Amount
FairValueLiabilitiesLevel1ToLevel2TransferAmount
0
CY2022Q4 dhacu Fair Value Liabilities Level1 To Level2 Transfer Amount
FairValueLiabilitiesLevel1ToLevel2TransferAmount
0

Files In Submission

Name View Source Status
0001104659-23-060899-index-headers.html Edgar Link pending
0001104659-23-060899-index.html Edgar Link pending
0001104659-23-060899.txt Edgar Link pending
0001104659-23-060899-xbrl.zip Edgar Link pending
dhacu-20230331.xsd Edgar Link pending
dhacu-20230331x10q.htm Edgar Link pending
dhacu-20230331xex31d1.htm Edgar Link pending
dhacu-20230331xex31d2.htm Edgar Link pending
dhacu-20230331xex32d1.htm Edgar Link pending
dhacu-20230331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
dhacu-20230331_cal.xml Edgar Link unprocessable
dhacu-20230331_def.xml Edgar Link unprocessable
dhacu-20230331_pre.xml Edgar Link unprocessable
dhacu-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dhacu-20230331x10q_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending